

Sascha Pahernik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10904341/publications.pdf>

Version: 2024-02-01

95
papers

3,620
citations

185998

28
h-index

143772

57
g-index

95
all docs

95
docs citations

95
times ranked

4847
citing authors

#	ARTICLE	IF	CITATIONS
1	Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. <i>Kidney International</i> , 2015, 87, 74-84.	2.6	327
2	A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. <i>European Urology</i> , 2016, 69, 94-102.	0.9	201
3	180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial – The GOLIATH Study. <i>European Urology</i> , 2014, 65, 931-942.	0.9	189
4	The Value of PSA Density in Combination with PI-RADS _{v2} for the Accuracy of Prostate Cancer Prediction. <i>Journal of Urology</i> , 2017, 198, 575-582.	0.2	179
5	A Novel Stereotactic Prostate Biopsy System Integrating Pre-Interventional Magnetic Resonance Imaging and Live Ultrasound Fusion. <i>Journal of Urology</i> , 2011, 186, 2214-2220.	0.2	165
6	Small Renal Tumors: Correlation of Clinical and Pathological Features With Tumor Size. <i>Journal of Urology</i> , 2007, 178, 414-417.	0.2	140
7	Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?. <i>BJU International</i> , 2008, 102, 1413-1418.	1.3	119
8	A European Multicenter Randomized Noninferiority Trial Comparing 180 W GreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study. <i>Journal of Urology</i> , 2015, 193, 570-578.	0.2	117
9	SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. <i>European Urology</i> , 2015, 68, 837-847.	0.9	116
10	Nephron Sparing Surgery for Renal Cell Carcinoma With Normal Contralateral Kidney: 25 Years of Experience. <i>Journal of Urology</i> , 2006, 175, 2027-2031.	0.2	107
11	Vaporization of prostates of ≥ 80 mL using a potassium-titanyl-phosphate laser: midterm results and comparison with prostates of < 80 mL. <i>BJU International</i> , 2008, 102, 322-327.	1.3	95
12	Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). <i>European Urology</i> , 2013, 64, 472-477.	0.9	91
13	Elective Nephron Sparing Surgery for Renal Cell Carcinoma Larger Than 4 cm. <i>Journal of Urology</i> , 2008, 179, 71-74.	0.2	87
14	Impact of Complete Bladder Neck Preservation on Urinary Continence, Quality of Life and Surgical Margins After Radical Prostatectomy: A Randomized, Controlled, Single Blind Trial. <i>Journal of Urology</i> , 2013, 189, 891-898.	0.2	82
15	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>European Urology</i> , 2014, 66, 577-583.	0.9	76
16	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. <i>European Urology</i> , 2016, 70, 447-455.	0.9	73
17	Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma – results from a comprehensive multicentre database (CORONA/SATURN project). <i>BJU International</i> , 2013, 112, 909-916.	1.3	69
18	Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound. <i>Journal of Urology</i> , 2018, 199, 983-989.	0.2	67

#	ARTICLE	IF	CITATIONS
19	Multimedia Support for Improving Preoperative Patient Education: A Randomized Controlled Trial Using the Example of Radical Prostatectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 15-23.	0.7	64
20	Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Current Urology Reports</i> , 2014, 15, 404.	1.0	60
21	Rectosigmoid Pouch (Mainz Pouch II) in Children. <i>Journal of Urology</i> , 2006, 175, 284-287.	0.2	51
22	Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. <i>Nature Communications</i> , 2016, 7, ncomms11845.	5.8	44
23	Decision-making in localized prostate cancer: lessons learned from an online support group. <i>BJU International</i> , 2011, 107, 1570-1575.	1.3	41
24	Selective Transarterial Embolization for Posttraumatic Renal Hemorrhage: A Second Try is Worthwhile. <i>Journal of Urology</i> , 2011, 185, 1751-1755.	0.2	40
25	Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. <i>BJU International</i> , 2007, 100, 26-29.	1.3	39
26	Navigated renal access using electromagnetic tracking: an initial experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 1307-1312.	1.3	35
27	Prognostic Stratification of Localized Renal Cell Carcinoma by Tumor Size. <i>Journal of Urology</i> , 2008, 180, 62-67.	0.2	34
28	Impact of Clinical and Histopathological Parameters on Disease Specific Survival in Patients with Collecting Duct Renal Cell Carcinoma: Development of a Disease Specific Risk Model. <i>Journal of Urology</i> , 2013, 190, 458-463.	0.2	31
29	Two decades' experience with a prospective biobank for urologic oncology: research, clinical care, and the patients' view. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 990-996.	0.8	28
30	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. <i>Journal of Urology</i> , 2015, 194, 304-309.	0.2	28
31	The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker. <i>Oncotarget</i> , 2016, 7, 418-432.	0.8	28
32	Urinary Diversion. <i>Deutsches Arzteblatt International</i> , 2012, 109, 617-22.	0.6	27
33	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. <i>Journal of Urology</i> , 2015, 193, 436-442.	0.2	27
34	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. <i>Scientific Reports</i> , 2018, 8, 16708.	1.6	27
35	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. <i>Journal of Surgical Oncology</i> , 2016, 114, 764-768.	0.8	26
36	Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 221-228.	1.4	26

#	ARTICLE	IF	CITATIONS
37	MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. <i>Oncotarget</i> , 2017, 8, 1046-1057.	0.8	26
38	Nephron sparing surgery for renal cell carcinoma in a solitary kidney. <i>World Journal of Urology</i> , 2007, 25, 513-517.	1.2	25
39	Multimedia support in preoperative patient education for radical prostatectomy: The physicians' point of view. <i>Patient Education and Counseling</i> , 2012, 87, 239-242.	1.0	25
40	Defined Conditions for the Isolation and Expansion of Basal Prostate Progenitor Cells of Mouse and Human Origin. <i>Stem Cell Reports</i> , 2015, 4, 503-518.	2.3	24
41	Complete bladder neck preservation promotes long-term post-prostatectomy continence without compromising midterm oncological outcome: analysis of a randomised controlled cohort. <i>World Journal of Urology</i> , 2018, 36, 349-355.	1.2	23
42	Phantom Study of a Novel Stereotactic Prostate Biopsy System Integrating Preinterventional Magnetic Resonance Imaging and Live Ultrasonography Fusion. <i>Journal of Endourology</i> , 2012, 26, 807-813.	1.1	22
43	Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 637-644.	0.8	22
44	Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?. <i>BJU International</i> , 2009, 103, 877-882.	1.3	21
45	Preoperative decision making for renal cell carcinoma: Cystic morphology in cross-sectional imaging might predict lower malignant potential. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e1-37.e6.	0.8	21
46	Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 433.e1-433.e8.	0.8	21
47	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. <i>Oncotarget</i> , 2019, 10, 17-29.	0.8	21
48	CONVERSION FROM COLONIC OR ILEAL CONDUIT TO CONTINENT CUTANEOUS URINARY DIVERSION. <i>Journal of Urology</i> , 2004, 171, 2293-2297.	0.2	20
49	External validation of novel magnetic resonance imaging-based models for prostate cancer prediction. <i>BJU International</i> , 2020, 125, 407-416.	1.3	20
50	Genomic features of renal cell carcinoma with venous tumor thrombus. <i>Scientific Reports</i> , 2018, 8, 7477.	1.6	19
51	<scp>PBRM1</scp> (<scp>BAF180</scp>) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas. <i>Journal of Pathology</i> , 2015, 237, 460-471.	2.1	18
52	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	0.5	18
53	Survival in prostate cancer patients 70 years after radical prostatectomy and comparison to younger patients. <i>World Journal of Urology</i> , 2009, 27, 637-642.	1.2	17
54	Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e145-e152.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma. <i>Neoplasia</i> , 2014, 16, 1028-1035.	2.3	15
56	Prognostic relevance of androgen receptor expression in renal cell carcinomas. <i>Oncotarget</i> , 2017, 8, 78545-78555.	0.8	15
57	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 74049-74057.	0.8	14
58	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e11-79.e17.	0.8	14
59	Risk factors and clinical management of haemorrhage after open nephron-sparing surgery. <i>BJU International</i> , 2010, 106, 1488-1493.	1.3	13
60	Preoperative Hydronephrosis Predicts Advanced Bladder Cancer but Is Not an Independent Factor for Cancer-Specific Survival after Radical Cystectomy. <i>Urologia Internationalis</i> , 2011, 86, 25-30.	0.6	13
61	The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. <i>World Journal of Urology</i> , 2014, 32, 1537-1542.	1.2	13
62	Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e379-e385.	0.9	13
63	Risk of Radiation-Induced Cataracts: Investigation of Radiation Exposure to the Eye Lens During Endourologic Procedures. <i>Journal of Endourology</i> , 2018, 32, 897-903.	1.1	13
64	Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. <i>BJU International</i> , 2021, 127, 544-552.	1.3	13
65	Prognostic Factors Influencing Long-Term Survival of Patients Undergoing Nephron-Sparing Surgery for Nonmetastatic Renal-Cell Carcinoma (RCC) with Imperative Indications. <i>Annals of Surgical Oncology</i> , 2010, 17, 544-551.	0.7	11
66	Intraoperative electron radiation therapy (IOERT) in patients with locally recurrent renal cell carcinoma. <i>Radiation Oncology</i> , 2013, 8, 282.	1.2	11
67	Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma ¹ Present address: Department of Urology, University Hospital Frankfurt, Germany. ² Equal contributions.. <i>Urologic Oncology: Seminars and Original Investigations</i> . 2014. 32. 877-884.	0.8	11
68	Interdisciplinary counseling service for renal malignancies: A patient-centered approach to raise guideline adherence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e1-23.e7.	0.8	11
69	Patients' View of Their Preoperative Education for Radical Prostatectomy: Does It Change After Surgery?. <i>Journal of Cancer Education</i> , 2012, 27, 377-382.	0.6	10
70	Pitfalls of electromagnetic tracking in clinical routine using multiple or adjacent sensors. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2013, 9, 268-273.	1.2	10
71	Initial Experience with Teme sirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response. <i>Urologia Internationalis</i> , 2011, 86, 256-260.	0.6	8
72	Combination of Robotic Pyeloplasty and Percutaneous Renal Surgery for Simultaneous Treatment of Ureteropelvic Junction Obstruction and Calyx Stones. <i>Urologia Internationalis</i> , 2021, 105, 637-641.	0.6	8

#	ARTICLE	IF	CITATIONS
73	Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 238.e9-238.e17.	0.8	7
74	Pediatric Case Report on Magnetic Resonance Imaging/Transrectal Ultrasound-fusion Biopsy of Rhabdomyosarcoma of the Bladder/Prostate: A New Tool To Reduce Therapy-associated Morbidity?. <i>Urology</i> , 2013, 81, 417-420.	0.5	6
75	Ureterocystoneostomy in complex oncological cases with an œLeibelhoerâ€-modified Boari bladder flap. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 1271-1278.	0.8	6
76	Small renal cell carcinoma: oncological outcome with tumour size. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 432-435.	1.4	5
77	Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. <i>World Journal of Urology</i> , 2015, 33, 833-839.	1.2	5
78	Conversion from colonic conduit into recto-sigmoid pouch (Mainz pouch II). <i>BJU International</i> , 2006, 97, 157-160.	1.3	4
79	PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablativ focal therapy. <i>World Journal of Urology</i> , 2012, 30, 91-95.	1.2	4
80	Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma â€” Prognostic and Translational Implications. <i>Translational Oncology</i> , 2015, 8, 480-486.	1.7	4
81	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA) Tj ETQq1 1 0.784304rgBT /Overlock		
82	Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4591-TPS4591.	0.8	4
83	Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. <i>Oncotarget</i> , 2018, 9, 22537-22545.	0.8	4
84	Risk factors of long-term postoperative renal function after partial nephrectomy in a solitary kidney. <i>Open Life Sciences</i> , 2017, 12, 481-488.	0.6	3
85	Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL. <i>Future Science OA</i> , 2018, 4, FSO299.	0.9	3
86	Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. <i>Journal of Cancer</i> , 2017, 8, 507-512.	1.2	2
87	Modulating the Heat Sensitivity of Prostate Cancer Cell Lines In Vitro: A New Impact for Focal Therapies. <i>Biomedicines</i> , 2020, 8, 585.	1.4	2
88	Neural Networks Modeling for Prediction of Required Resources for Personalized Endourologic Treatment of Urolithiasis. <i>Journal of Personalized Medicine</i> , 2022, 12, 784.	1.1	2
89	Renal cell cancer—a multimodal approach to preserving renal function and improving survival. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3086-3088.	0.4	1
90	Risk factors for long-term outcome in photoselective vaporization of the prostate. <i>Scandinavian Journal of Urology</i> , 2016, 50, 313-318.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Response to Bieko re: Risk of Radiation-Induced Cataracts: Investigation of Radiation Exposure to the Eye Lens During Endourological Procedures. <i>Journal of Endourology</i> , 2018, 32, 905-906.	1.1	1
92	A Forgotten Ureteral Stent: Potential Risks for the Urinary Function. <i>Urologia Internationalis</i> , 2022, 106, 209-212.	0.6	1
93	Positive surgical margins after partial nephrectomy. <i>Nature Reviews Urology</i> , 2010, 7, 240-242.	1.9	0
94	Results of a Patient Survey for Assessment Services in Renal Transplant Patients With a History of Cancer. <i>Progress in Transplantation</i> , 2017, 27, 365-368.	0.4	0
95	Single-Center Evaluation of Treatment Success Using Two Different Protocols for MRI-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 782546.	1.3	0